How difficult is it to bring all these products to market? What makes nasal delivery systems more challenging than solid dosage forms? How safe is nasal drug delivery? Are there such things as safe excipients? How does all this fit within the regulatory environment in Europe and the USA? This conference seeks to explore these and other questions within the field of nasal drug delivery while reviewing interesting new data and innovative technologies. Leading authorities in nasal drug delivery will cover relevant aspects of nasal physiology, anatomy, absorption of a variety of drugs, in various phases of drug development, and new drugs entering the market. In addition, the conference will discuss nasal delivery to the sinuses and interesting case histories.
Your next step is to call us now on +44 (0)20 7749 4730 or email us at firstname.lastname@example.org or use our contact form and find out how we can help. There are no commitments, and if we cannot help our advice and recommendations are free of charge.
If you would like to contribute a presentation at the 2019 event please contact email@example.com
Managing directors, medical directors, head of regulatory affairs and quality assurance, senior executives in research and development, registration, marketing and all departments that may be involved in nasal drug delivery, or who wish to understand the potential of this alternative therapeutic route. Those already involved in Nasal Drug Delivery will benefit from updating their knowledge and sharing experiences with some of the leading practitioners in this field. If you are involved in nasal drug delivery or are just considering the potential, this conference is an excellent route to understanding all aspects from the basic physiology through to launching a successful product.
1. Gain an update on the very latest scientific developments and technology advances in this field.
2. Hear from an unrivalled panel of expert speakers.
3. An excellent networking opportunity to build business relationships.
Nasal drugs to treat nasal disorders: a comprehensive review
Professor Michael S. Benninger, Chairman The Head and Neck Institute, Professor of Surgery, Lerner College of Medicine, The Cleveland Clinic, USA
Nasal drug delivery challenges
Dr Julie Suman, President Next Breath, USA
Nasal formulation of drugs
Dr Regina Scherliess, Christian Albrecht University of Kiel, Department of Pharmaceutics and Biopharmaceutics, Germany
Nose to brain drug delivery of Oxytocin
Professor Yannis Paloyelis, Lecturer in Neruoscience and Psychology, Neuroimaging Department, Kings College, UK
Methodology for comparing particle size of nasal spray formulations
David Exline, President, Gateway Analytical, USA
XHANCE™ – A new approach to reach the target sites of inflammation in chronic rhinosinusitis
Dr Per Gisle Djupesland, CSO, OptiNose, Norway
Retronose concept: Aerosol delivery by oral route for nasal drug targeting
Pascale Farjas, Global Category Manager – Ear, Nose and Throat, Nemera and Laurent Vecellio, Researcher, INSERM, France
OTC Opportunities & Challenges for Nasal Drug Delivery
Sriman Banerjee, GSK
Drinks reception for delegates and speakers
Review of nasal drug delivery devices
Dr René Bommer, General Manager, pharmAccel Consulting, Germany
Advanced water technology: a unique platform for innovative OTC products
Georges Bouille, CEO, ADWATISs SA and Jean-Michel Verjus, Pharmacist, ADWATIS SA, Switzerland
FRI as a tool to optimize regional delivery of nasal aerosols
Dr Wim Vos, Chief Operating Officer, FLUIDDA, Belgium
Digital healthcare: Improving patient health outcomes through connected devices
Sai Shankar, Director, Business Development – Connected Devices, Aptar Pharma, France
Qualification of new nasal drug delivery systems for existing drugs
Thomas Grinnan, Senior Commercial Director, Healthcare, Silgan Dispensing Systems, France
Aseptic vs non-aseptic filling strategies for nasal spray trends and the evidence behind
Cecilie Vo, Quality Advisor and Business Development Representative, Curida, Norway
What are Chemisimilars and what’s the problem?
Dr John Warren, Director, Medicines Assessment, UK
Dr. René Bommer is a founder and an owner of pharmAccel Consulting.
He received his Ph.D. in Chemistry from the University of Constance in Germany in 1990. After research positions at the Scripps Clinic in San Diego, USA , at Altana Pharma Germany (now Takeda) and a lectureship at the University of Buenos Aires he joined the device developing and manufacturing company Ing. Erich Pfeiffer GmbH in Germany and became a Director of Business Development.
In 2007 René founded a consulting company with a focus on delivery devices. pharmAccel Consulting delivers a service to support an accelerated entry into the market with consideration of technical, regulatory, marketing and pharmaeconomical aspects of the drug delivery device business.
Dr. Julie D. Suman, R.Ph., Ph.D., is a co-founder and President of Next Breath, LLC, an incubator company located at the UMBC Technology Center. Next Breath, which incorporated in April 2002, is a contract research organisation dedicated to the development of nasal and inhalation delivery systems. She directs the contract research division that supports product development for North American and European clients in the pharmaceutical, biotechnology and medical device markets.
Julie holds a B.S. in Pharmacy from Duquesne University (1996) and a Ph.D. in Pharmaceutical Sciences from the University of Maryland, Baltimore (2002). She is a licensed Maryland pharmacist and a member of the Maryland Pharmacy Volunteer Corp.
Julie has also been an affiliate assistant professor in the Department of Pharmaceutics at Virginia Commonwealth University since 2009.
Dr. Michael S. Benninger has been the Chairman of the Head and Neck Institute at The Cleveland Clinic since 2008. Previously he was the Chairman of the Department of Otolaryngology-Head and Neck Surgery at Henry Ford Health System in Detroit, Michigan.
He has also been involved in Regional, National and International medical organizations. He served on the Board of Directors of the American Academy of Otolaryngology-Head and Neck Surgery for 12 years, having been a former Vice President and Chairman of the Board of Governors.
Dr. Benninger is on the Board of Directors of the Voice Foundation and the International Association of Phonosurgeons, and has recently been on the Executive Council of the Triological Society.
In addition to his numerous professional pursuits Dr. Benninger has authored 6 books, including his most recent books, “The Performer’s Voice” and “The Singer’s Voice”. He has written over 100 scientific articles, focusing primarily on voice care and laryngology, nasal and sinus disease and health care management. Dr. Benninger has also lectured extensively across the US and throughout the world.
|11-12 Apr 2019|
|11-12 Apr 2019||Venue not yet confirmed||GBP 1,499.00
+ VAT @ 20.00%